Merck Canada Inc.

Merck Sharp + Dohme Corp.

Genentech, Inc.

Merck Frosst Canada, Inc.

Jason Burch

Alan B Northrup

Yongxin Han

Michael D Altman

Solomon D Kattar

Andrew M Haidle

Michael Hale Reutershan

John Michael Ellis

Jongwon Lim

Matthew Christopher

Sandra Lee Knowles

Anthony Donofrio

Marc Blouin

Joel S Robichaud

Bernard Cote

Adam J Schell

Julie Farand

Hua Zhou

Maria Emilia Di Francesco

Daniel Guay

Xiaojing Wang

Jacques Yves Gauthier

Michelle R Machacek

Wesley Peter Blackaby

Andrew Sharpe

Minghua Sun

Claudio F Sturino

Kenneth L Arrington

Christian Fischer

Brandon Mitsuo Taoka

Kaleen Konrad Childers

Alastair James Hodges

Kerrie Spencer

Po-wai Yuen

Steven T Staben

Jianwen A Feng

B Wesley Trotter

Chun Sing Li

David Joseph Guerin

Georgette M Castanedo

Michel L Belley

Ryan D Otte

Claude Dufresne

John Colucci

Brian M Andresen

Alessia Petrocchi

Tony Siu

James Patrick Jewell

Jonathan B Grimm

Nicole Blaquiere

Guosheng Wu

Carl Berthelette

Christian Beaulieu

Vouy Linh Truong

Christophe Mellon

Michael Boyd

Graham Frank Smith

Mario Girard

Eric Thomas Romeo

Baihua Hu

Brendan O'Boyle

Chaomin Li

Anna A Zabierek

Jean-Francois Fournier

Denis Deschenes

Miguel St-Onge

Brandon M Taoka

Jean Francois Fournier

Danny Gauvreau

Kristina Dupont-Gaudet

Natalie Nguyen

Alan B Northhrup

Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein Ris a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

The invention relates to compounds of Formula (0): 

Alkynyl alcohols and methods of use

The present invention provides novel imidazole analogs of Formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

Imidazolyl analogs as syk inhibitors

The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, C, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase. 

Substituted pyridine spleen tyrosine kinase (SYK) inhibitors

The invention provides certain substituted phenyl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk). 

Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors

The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included. (Formulas I and II). 

Thiophenecarboxamide derivatives as EP4 receptor ligands

The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

Aminopyrimidines as Syk inhibitors

The invention is directed to &#x3b2;-carboline sulphonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, inflammation, osteoarthritis, and rheumatoid arthritis. Pharmaceutical compositions and methods of use are also included.

Beta carboline sulphonylurea derivatives as EP4 receptor antagonists

Aminopyrimidines as SYK inhibitors

Heteroaromatic compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R, R, R, Rand Rare defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Non-nucleoside reverse transcriptase inhibitors

The invention is directed to quinoline derivatives as prostaglandin E type receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. The derivatives have the following structure of formula (I): wherein A and B represents either a nitrogen atom or a CH group with the proviso that they cannot both simultaneously be CH, Q can represent a nitrogen or a carbon atom, and Y and Z are either a nitrogen atom, a N(O) group or a C(R) group. Pharmaceutical compositions comprising the derivatives of formula (I) are also included. 

Quinoline derivatives as EP4 antagonists

The invention is directed to naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.

Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists

Growing community of inventors

Redwood City, CA, United States of America

Jason Burch